Next-Generation and Experimental Oncology Therapies
Session Overview
The frontier of oncology therapeutics is being redrawn by a wave of platform technologies that move beyond small molecules and monoclonal antibodies. This new generation—encompassing gene editing, RNA-based drugs, nanotechnology, and synthetic biology—offers the potential to target previously “undruggable” pathways, achieve exquisite cell-type specificity, and create dynamic, programmable medicines. This session brings together pioneers in bioengineering, translational science, and early-phase clinical trials to examine the most promising experimental platforms and the unique challenges of translating them from concept to clinic.
Why This Session Matters Now
After decades of incremental progress in established modalities, these emerging platforms represent a potential paradigm shift. However, their complexity introduces novel scientific, manufacturing, safety, and regulatory hurdles. The path from a compelling in vitro concept to a viable human therapeutic is exceptionally demanding for these advanced modalities. This session addresses the critical juncture where revolutionary science meets the practical realities of drug development, focusing on the innovative methodologies required to de-risk and accelerate the journey of next-generation agents.
Key Scientific and Clinical Themes
Gene Editing and Gene Therapy Approaches
Examination of CRISPR/Cas and other editing systems for in vivo and ex vivo applications, including correcting driver mutations, disrupting oncogenes, engineering immune cells, and the challenges of delivery, specificity, and long-term safety monitoring.
RNA-Based and Nucleic Acid Therapeutics
Analysis of the expanding toolbox of RNA medicines—from siRNA and antisense oligonucleotides to mRNA vaccines and circular RNAs—for silencing oncogenes, restoring tumor suppressors, and expressing therapeutic proteins within the tumor microenvironment.
Cell-Free and Nanotechnology-Based Drug Delivery
Focus on the design of advanced nanocarriers (lipid nanoparticles, polymers, inorganic particles) for targeted delivery of nucleic acids, chemo-, radio-, and immunotherapeutics, with an emphasis on overcoming biological barriers and enhancing tumor accumulation.
Synthetic Biology and Novel Therapeutic Platforms
Discussion of engineered living medicines (e.g., bacteria), logic-gated CAR-T cells, proteolysis-targeting chimeras (PROTACs), and other molecular machines designed to sense and respond to the dynamic tumor state with high precision.
First-in-Human and Early-Phase Oncology Trials
Exploration of innovative trial designs for complex therapeutic platforms, including staggered enrollment, novel toxicity grading, integrated biomarker strategies, and the use of translational endpoints to inform go/no-go decisions.
Translational Pathways from Bench to Bedside
Critical appraisal of the multidisciplinary ecosystem required for success, including scalable GMP manufacturing, predictive preclinical models, regulatory science for novel modalities, and fostering academia-industry partnerships.
Nature of Research in This Field
Research in this domain is characterized by extremely high-risk, high-reward science published in leading interdisciplinary journals. The literature is a mix of groundbreaking primary research papers establishing new platforms and forward-looking perspective articles. Robust clinical literature is sparse by definition, as most approaches are in preclinical or early clinical stages. The field is defined by rapid iteration, where technological breakthroughs in one area (e.g., LNP delivery for mRNA) can unlock entire new classes of drugs.
Who Should Attend
This session is designed for:
- Translational scientists, bioengineers, and chemical biologists
- Early-phase clinical trialists and experimental therapeutics specialists
- Researchers in drug delivery, nanotechnology, and gene editing
- Regulatory scientists and professionals from biotech/pharma in novel modalities
- Venture capitalists and technology transfer officers focused on oncology innovation
- Fellows and trainees interested in the cutting edge of cancer therapy development
Session Perspective
The next generation of cancer cures may not look like a pill or an infusion bag, but like a programmable nanofactory or a genetically rewritten cell. This session provides a platform to look beyond today’s clinical trial portfolio to the foundational technologies that will define oncology a decade from now. By confronting the immense translational challenges head-on—from delivery and manufacturing to safety and trial design—the discussion aims to accelerate the responsible and effective translation of these extraordinary scientific capabilities into reliable, accessible medicines for patients.
If your research aligns with this session, we invite you to submit an abstract for consideration.
